Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:35:47.012Z.
Consensus retrieved: 2026-10-06T09:28:28.878Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:35:47.012Z.
Quote observation: 2026-10-06T13:34:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1148a26bf5d8a77c385830e28adfe1a3226667ff180e3eaa52d15dba3998f7d4
Forward PE Ratio (N/A) = Dated Quote Price ($0.77) / Consensus Forward EPS ($-464.00)
FORWARD PE RATIO
N/A
Bluejay Diagnostics, Inc.
Market Cap
$800351.00
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $800351.00 | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $872428.00 | N/A |
| Bone Biologics Corporation (BBLG)vs › | $897948.00 | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A |
| CDT Equity Inc. (CDT)vs › | $685948.00 | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | N/A |
| HCW Biologics Inc. (HCWB)vs › | $563178.00 | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.15M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-464.00 | $-464.00 – $-464.00 | 1 | n/m |
| 2027-12-31 | $-32.00 | $-32.00 – $-32.00 | 1 | n/m |
| 2028-12-31 | $400.00 | $400.00 – $400.00 | 1 | 0.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
